TWI520951B - 用於治療粘膜炎的化合物 - Google Patents

用於治療粘膜炎的化合物 Download PDF

Info

Publication number
TWI520951B
TWI520951B TW101117238A TW101117238A TWI520951B TW I520951 B TWI520951 B TW I520951B TW 101117238 A TW101117238 A TW 101117238A TW 101117238 A TW101117238 A TW 101117238A TW I520951 B TWI520951 B TW I520951B
Authority
TW
Taiwan
Prior art keywords
group
independently
alkyl
npl
groups
Prior art date
Application number
TW101117238A
Other languages
English (en)
Chinese (zh)
Other versions
TW201247654A (en
Inventor
理查W 史考特
波澤納 科爾恰克
Original Assignee
塞爾西優蒂克斯公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 塞爾西優蒂克斯公司 filed Critical 塞爾西優蒂克斯公司
Publication of TW201247654A publication Critical patent/TW201247654A/zh
Application granted granted Critical
Publication of TWI520951B publication Critical patent/TWI520951B/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1825Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
TW101117238A 2011-05-16 2012-05-15 用於治療粘膜炎的化合物 TWI520951B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161486455P 2011-05-16 2011-05-16

Publications (2)

Publication Number Publication Date
TW201247654A TW201247654A (en) 2012-12-01
TWI520951B true TWI520951B (zh) 2016-02-11

Family

ID=47175383

Family Applications (1)

Application Number Title Priority Date Filing Date
TW101117238A TWI520951B (zh) 2011-05-16 2012-05-15 用於治療粘膜炎的化合物

Country Status (14)

Country Link
US (6) US8802683B2 (enExample)
EP (1) EP2709619B1 (enExample)
JP (1) JP5833745B2 (enExample)
KR (1) KR102012164B1 (enExample)
CN (1) CN103957710B (enExample)
AU (1) AU2012255935B2 (enExample)
CA (1) CA2836099C (enExample)
DK (1) DK2709619T3 (enExample)
IL (1) IL229381B (enExample)
MX (1) MX2013013330A (enExample)
RU (1) RU2606128C2 (enExample)
TW (1) TWI520951B (enExample)
WO (1) WO2012158672A2 (enExample)
ZA (1) ZA201308541B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090092574A1 (en) 2006-12-29 2009-04-09 Scott Richard W Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
RU2606128C2 (ru) * 2011-05-16 2017-01-10 Селлсьютикс Корпорейшн Соединения для применения в лечении мукозита
HK1210437A1 (en) * 2012-12-18 2016-04-22 Jawaharlal Nehru Centre For Advanced Scientific Research Antimicrobial compounds, their synthesis and applications thereof
EP2956437B1 (en) * 2013-02-15 2023-05-10 Technische Universität Berlin Albicidin derivatives for the treatment of bacterial infections
ES2835382T3 (es) * 2013-03-15 2021-06-22 Boehringer Ingelheim Animal Health Usa Inc Composiciones de poliamidas antimicrobianas y tratamiento de la mastitis
JP6047203B2 (ja) * 2015-02-20 2016-12-21 セルセウティックス コーポレイション 消化管の炎症性疾患の予防および/または治療のための宿主防御タンパク質(hdp)模倣薬
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
JP7050165B2 (ja) 2018-02-26 2022-04-07 ギリアード サイエンシーズ, インコーポレイテッド Hbv複製阻害剤としての置換ピロリジン化合物
US11771694B2 (en) 2020-06-05 2023-10-03 Innovation Pharmaceuticals Inc. Arylamide compounds for treatment and prevention of viral infections
KR20240053580A (ko) 2021-08-30 2024-04-24 유니켐 레버러토리스 리미티드 염증성 질환의 치료용 단백질 조성물
CN114890982A (zh) * 2022-05-16 2022-08-12 内蒙古大学 一种季铵盐修饰的二苯并噻吩亚砜衍生物的制备方法
CN117402075A (zh) * 2023-10-17 2024-01-16 厦门大学深圳研究院 一种具有特异性抗肿瘤活性的可见光响应的人工h+/ci-离子通道的制备

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3496179A (en) 1967-10-11 1970-02-17 Pfizer & Co C 2-amino-3,4-dihydroquinazolines
CA2128612C (en) 1992-01-23 1999-06-15 Mamoru Tomita Antimicrobial agents and method for treating products therewith
US6025326A (en) 1995-07-07 2000-02-15 Intrabiotics Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of oral mucositis
US5994306A (en) * 1995-11-22 1999-11-30 Intrabiotics Pharmaceuticals, Inc. Fine-tuned protegrins
JP3090125B2 (ja) 1997-08-26 2000-09-18 千寿製薬株式会社 ソフトコンタクトレンズ用の眼科用組成物、ソフトコンタクトレンズの濡れ増強方法およびテルペノイドの吸着抑制方法
WO2000010990A2 (en) 1998-08-20 2000-03-02 University Of North Carolina At Chapel Hill Dicationic dibenzofuran and dibenzothiophene compounds and methods of use thereof
US20040152664A1 (en) 1998-09-02 2004-08-05 Allergan, Inc. Prednisolone compositions
US6440964B1 (en) 1998-09-30 2002-08-27 Alcon Manufacturing, Ltd. Compositions and methods for treating ophthalmic and otic infections
US6482799B1 (en) 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
JP2001261674A (ja) 2000-03-22 2001-09-26 Mitsui Chemicals Inc ベンゾチオフェン誘導体およびそれを有効成分として含有する核内レセプター作動薬
FR2813080B1 (fr) 2000-08-17 2002-11-29 Stago Diagnostica Peptides anti-heparine
ES2311035T3 (es) 2000-11-08 2009-02-01 Fxs Ventures, Llc Soluciones oftalmicas y para lentes de contacto mejoradas que contienen formas de vitamina b.
JP2004520473A (ja) * 2001-01-18 2004-07-08 ジェンザイム コーポレーション 抗菌剤としてのヨネンポリマーおよびその使用
EP1372551B1 (en) 2001-03-08 2008-09-17 The Trustees Of The University Of Pennsylvania Facially amphiphilic polymers as anti-infective agents
US7629317B2 (en) 2001-03-29 2009-12-08 The University Of Chicago Control of growth and repair of gastro-intestinal tissues by gastrokines and inhibitors
AR034372A1 (es) 2001-06-08 2004-02-18 Novartis Ag Composiciones farmaceuticas
US6841578B2 (en) * 2001-08-16 2005-01-11 Stephen T. Sonis Treatment and prevention of mucositis in cancer patients
CA2487454A1 (en) 2002-05-28 2003-12-04 The Trustees Of The University Of Pennsylvania Methods, systems, and computer program products for computational analysis and design of amphiphilic polymers
CA2489378A1 (en) 2002-06-13 2003-12-24 The Trustees Of The University Of Pennsylvania Methods, systems, and computer program products for simulating biomembranes using coarse grain models
AU2003291087A1 (en) * 2002-11-19 2004-06-15 Genzyme Corporation Ionene oligomers and polymers
WO2004082634A2 (en) 2003-03-17 2004-09-30 The Trustees Of The University Of Pennsylvania Facially amphiphilic polymers and oligomers and uses thereof
AU2003249114A1 (en) 2003-03-20 2004-10-11 Shiseido International France Cosmetic composition
US20040202687A1 (en) 2003-04-14 2004-10-14 Babu M.K. Manoj Ciprofloxacin formulations and methods of making and using the same
US20050059639A1 (en) 2003-09-11 2005-03-17 Wei Edward T. Ophthalmic compositions and method for treating eye discomfort and pain
US20050065091A1 (en) 2003-09-18 2005-03-24 Gholam Peyman Stabilized ocular solutions
CA2554163A1 (en) 2004-01-23 2005-08-11 The Trustees Of The University Of Pennsylvania Facially amphiphilic polyaryl and polyarylalkynyl polymers and oligomers and uses thereof
CN102653515A (zh) 2004-06-15 2012-09-05 宝利麦迪克斯股份有限公司 聚阳离子化合物及其用途
WO2006132647A2 (en) 2004-07-23 2006-12-14 The Trustees Of The University Of Pennsylvania Antimicrobial copolymers and uses thereof
KR20080004475A (ko) 2005-02-25 2008-01-09 유니버시티 오브 매사추세츠 표면적으로 양친매성인 중합체 및 올리고머, 그 조성물 및암치료방법으로서의 그 용도
ATE485819T1 (de) * 2005-03-24 2010-11-15 Rottapharm Spa Benzamidin derivative zur behandlung und vorbeugung von mucositis
WO2006122162A2 (en) * 2005-05-10 2006-11-16 The University Of Chicago Use of peptides derived from the growth factor amp-18 for the treatment of mucositis
US7951829B2 (en) * 2006-05-03 2011-05-31 Janssen Pharmaceutica Nv Benzimidazole modulators of VR1
JP2008137978A (ja) 2006-12-05 2008-06-19 Canon Inc カルバゾール誘導体及びこれを用いた有機発光素子
US20090092574A1 (en) * 2006-12-29 2009-04-09 Scott Richard W Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
US20100297257A1 (en) 2007-11-09 2010-11-25 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs) Anticoagulant antagonist and hemophillia procoagulant
JP2011529502A (ja) * 2008-07-28 2011-12-08 ポリメディックス・インコーポレーテッド 抗マラリア化合物
US8278309B2 (en) * 2008-10-27 2012-10-02 Polymedix, Inc. Synthetic mimetics of host defense and uses thereof
BRPI0922947A2 (pt) * 2008-12-10 2015-08-25 Polymedix Inc Métodos para inibir o crescimento de uma espécie de mycobacterium, e para tratar um animal tendo uma infecção de mycobacterium, e, composto.
UA110323C2 (en) * 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
WO2011084970A1 (en) * 2010-01-07 2011-07-14 Polymedix Inc. Anti-heparin compounds
TW201208677A (en) * 2010-08-21 2012-03-01 Polymedix Inc Facially amphiphilic compounds, compositions, and uses thereof in treating cancer
RU2606128C2 (ru) * 2011-05-16 2017-01-10 Селлсьютикс Корпорейшн Соединения для применения в лечении мукозита
SG11201403215TA (en) * 2011-12-13 2014-09-26 Cellceutix Corp Cyclic compounds and methods of making and using the same
EP2804476A4 (en) * 2012-01-18 2016-01-06 Cellceutix Corp COMPOUNDS AND METHOD FOR THE TREATMENT OF CANDIDIASIS AND ASPERGILLUS INFECTIONS
US20140308317A1 (en) * 2012-12-10 2014-10-16 Cellceutix Corporation Polymeric Compounds And Methods Of Making And Using The Same
WO2014093231A2 (en) * 2012-12-10 2014-06-19 Cellceutix Corporation Hybrid compounds and methods of making and using the same
CN105246476B (zh) * 2013-05-28 2019-11-15 莫弗凯姆联合化学股份公司 含噁唑烷酮-喹诺酮的联合疗法在治疗细菌感染中的应用
JP6047203B2 (ja) * 2015-02-20 2016-12-21 セルセウティックス コーポレイション 消化管の炎症性疾患の予防および/または治療のための宿主防御タンパク質(hdp)模倣薬

Also Published As

Publication number Publication date
JP5833745B2 (ja) 2015-12-16
WO2012158672A3 (en) 2014-05-08
CN103957710B (zh) 2016-04-20
JP2014516033A (ja) 2014-07-07
US20160213668A1 (en) 2016-07-28
EP2709619A4 (en) 2015-04-22
US20170224640A1 (en) 2017-08-10
RU2606128C2 (ru) 2017-01-10
NZ618249A (en) 2016-03-31
CA2836099C (en) 2020-06-16
CN103957710A (zh) 2014-07-30
US20120295922A1 (en) 2012-11-22
KR102012164B1 (ko) 2019-08-20
US10603294B2 (en) 2020-03-31
KR20140078582A (ko) 2014-06-25
US9155738B2 (en) 2015-10-13
AU2012255935B2 (en) 2016-06-23
CA2836099A1 (en) 2012-11-22
US9457027B2 (en) 2016-10-04
US20140364364A1 (en) 2014-12-11
RU2013155678A (ru) 2015-06-27
ZA201308541B (en) 2015-04-29
US9795575B2 (en) 2017-10-24
EP2709619B1 (en) 2017-10-11
US20190282521A1 (en) 2019-09-19
US10206894B2 (en) 2019-02-19
DK2709619T3 (en) 2018-01-15
IL229381B (en) 2018-04-30
IL229381A0 (en) 2014-01-30
WO2012158672A2 (en) 2012-11-22
MX2013013330A (es) 2014-07-09
TW201247654A (en) 2012-12-01
EP2709619A2 (en) 2014-03-26
US20180064664A1 (en) 2018-03-08
US8802683B2 (en) 2014-08-12

Similar Documents

Publication Publication Date Title
TWI520951B (zh) 用於治療粘膜炎的化合物
AU2012255935A1 (en) Compounds for use in treatment of mucositis
US20110178104A1 (en) Anti-Heparin Compounds
WO2019205687A1 (zh) 苯基联三氮唑类mll1-wdr5蛋白-蛋白相互作用抑制剂
CN113811305A (zh) 带电的离子通道阻滞剂及其使用方法
KR20190016478A (ko) Lsd1 억제제를 이용한 다발성 경화증의 치료방법
AU2011334592B2 (en) Methods of treating eye diseases associated with inflammation and vascular proliferation
JP2008531585A (ja) 表面が両親媒性のポリマーおよびオリゴマー、それらの組成物そして癌治療方法におけるそれらの使用
US20120115877A1 (en) Facially Amphiphilic Compounds, Compositions, And Uses Thereof In Treating Cancer
CN103108632A (zh) 免疫调节的方法
NZ618249B2 (en) Compounds for use in treatment of mucositis

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees